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Objective: To determine the expression of non-muscle myosin heavy chain 9 (MYH9) in
osteosarcoma and its effect on the migration and invasion abilities of tumor cell.
Methods: A total of 65 cases of osteosarcoma and 20 cases with benign osteochondroma
who underwent resection operation in the Orthopaedics Department of our hospital from
January 1st 2009 to January 1st 2015 were selected. Their mRNA levels of MYH9 were
tested by qrt-PCR. Immunohistochemical method was used to examine the expression of
MYH9 in osteosarcoma and the correlation between the positive expression of MYH9
and the clinicopathological features of patients was illustrated by statistical analysis.
MYH9 was compounded artiﬁcially. The expression of MYH9 in SAOS2 osteosarcoma
cells was decreased by siRNA. Scratch test was used to determine the change of SAOS2
cell migration ability after MYH9 silence. Transwell assay was employed to detect the
change of cell invasion ability after MYH9 silence.
Results: The expression levels of mRNA of MYH9 and protein in osteosarcoma tissues
were signiﬁcantly higher than those in benign osteochondroma tissues. The high
expression of MYH9 in osteosarcoma tissues was apparently related to the high Enneking
classiﬁcation (III classiﬁcation) and lung metastasis. SiRNA of MYH9 could evidently
decrease the expression level of MYH9 in SAOS2. The down-regulated expression of
MYH9 could inhibit the migration and invasion abilities of SAOS2 cells.
Conclusions: MYH9 shows a trend of high expression in osteosarcoma tissues, and its
high expression is associated with features such as tumor invasion and metastasis. The
down-regulated MYH9 can realize an anti-tumor effect by inhibiting the migration and
invasion of osteosarcoma cells.1. Introduction
Osteosarcoma is a common malignant tumor in bone and
cartilaginous tissues [1]. It is the second factor causing cancerous
deaths among children and teenagers [2]. Although the
application of new chemotherapy and radiation therapy hasimproved the ﬁve-year survival rate for patients, the fatality
and disability rates caused by osteosarcoma migration still
maintain at high levels [3]. Therefore, searching for a molecular
therapeutic target for preventing osteosarcoma cells from
migration becomes one of the important methods to break this
“bottle neck” of the treatment of osteosarcoma.
Non-muscle myosin heavy chain 9 (MYH9) is located on
human chromosome 22q22.1 [4]. Protein products expressed by
it were called NMIA [Non-muscle myosin (IIA)] [5]. Previous
researches have manifested that MYH9 has played an
important regulatory role in diseases such as hereditary
diseases [6], hematologic diseases [7–10] and inﬂammations
[11]. Researchers have found in recent years that, to some
degree, MYH9 can promote the migration and invasion of
tumor cells. For example, Katono et al [12] found in non-ticle under the CC BY-NC-ND license (http://
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expressed MYH9 possessed a higher ratio of intra-tumor
vascular invasion and tumor node metastasis, and patients
with positive expressed MYH9 showed poorer prognosis, which
indicated that it was deﬁnitely worth exploring the value of
MYH9 in the aspects of tumor prognosis and migrant. How-
ever, the expression of MYH9 in osteosarcoma tissues and its
inﬂuences on the tumor migrant and invasion remain unknown
yet.
In this study, the correlation between the expression state of
MYH9 and clinical features and prognosis of tumor patients was
illustrated by analyzing the expression condition of MYH9 in
osteosarcoma tissues. SiRNA technology was employed for the
silence of the expression level of MYH9 in SAOS2 cells in vitro
and detecting the inﬂuence of down-regulated MYH9 expression
on the invasion ability of osteosarcoma cells, so as to provide
certain experiment basis to make MYH9 a prognosis evaluation
indicator and a biological therapeutic target for patients with
hepatocellular carcinoma.
2. Materials and methods
2.1. Materials
A total of 65 cases (45 males and 20 females) of osteosar-
coma with benign osteochondroma who had been treated with
resection operation in the Orthopaedics Department of our
hospital from January 1st 2009 to January 1st 2015 were
selected. There were 15 males and 20 females aging from 13 to
46 years. The median age was 33 years. At the same time, 20
cases of benign osteochondroma were selected, of which 15
cases were males and 5 were females aging from 17 to 44 years.
The median age was 31 years. The surgical specimens drawn its
materials from many parts and they were stored in 4% para-
formaldehyde solution or liquid nitrogen. RNA extraction kit
Fast200 was purchased from Shanghai Fastagen Biotechnology
Co., Ltd.; qRT-PCR kit (SYBR Green Quant qRT-PCR kit,
FP302) was bought from Beijing Tiangen Biotech Co., Ltd.; and
MYH9 and b-actin commercial primers were from Beijing Aoke
Biotech Co., Ltd. Human osteosarcoma cells SAOS2 were store
by our laboratory research center. DMEM liquid cell cultivation
medium was bought form Hyclone (USA). Fetal calf serum and
penicillin streptomycin were form Gibco (USA); and lipidosome
2000 was from Invitrogen Corporation (USA). Speciﬁc siRNA
od MYH9, negative control (NC) siRNA, rabbit-anti-human
MYH9 polyclonal antibody (sc-47201) and mouse anti human
b-actin monoclonal antibody (sc-47778) were purchased from
Santa Cruz (USA). Transwell essay were from Corning Cor-
poration (USA) and matrigel was gotten from BD Corporation
(USA).
2.2. Methods
2.2.1. qRT-PCR
According to the instruction of Fast200 reagent, tissues and
the total RNA of cells were extracted. In accordance with the
instruction, 20 mL reverse transcription PCR system were pre-
pared at ﬁrst and incubated at 37 C for 60 min to synthesize
cDNA. Then, 2 mL cDNA was taken as a template to prepare
20 mL real-time PCR reaction system. Bio-Rad Real-time PCR
instrument was used for the reaction. b-actin was served as areference object and the relative expression quantity of MYH9
mRNA was counted with the 2−△△Ct method.
2.2.2. Immuno-histochemical staining
Parafﬁn-embedded tissue sections were given antibody
thermal remediation, inhibited the activity of endogenous
peroxidase by hydrogen peroxide and then closed by goat
serum after dewaxing and hydration. 1:100 rabbit-anti-human
MYH9 compounded on the basis of 1 × PBS solution was
employed to cover those sections; they were reacted overnight
at 4 C and then the residual non-combined primary antibody
were eliminated. HRP-second antibody was used to combine
the speciﬁc primary antibody and DAB was applied for color-
ation. Ten visions of every section chosen randomly under
the ×400 ampliﬁcation were scored in accordance with the
standards described previously [13]. It was deﬁned as the
positive expression of MYH9 when the score was no less
than one.
2.2.3. SiRNA transfection
Before conducting the experiment, SAOS2 cells were culti-
vated and went down to 2–3 generations on 1 × DMEM medium
with 10% FBS. SAOS2 cells were incubated in 6-well culture
plates and cultured by a complete medium. After the conﬂuence
reached 50%–60%, the culture plates were poured out. PBS
solution was used to wash cells adequately. The transfection
groups included the MYH9 group that 200 pmol DMEM-made
MYH9 siRNA and 5 mL Lipofectamine™ 2000 were added in
each well and the NC group that 200 pmol DMEM-made NC
siRNA and 5 mL Lipofectamine™ 2000 were added in each
well. The ﬁnal culture volume was 2 mL. After cultivated in a
suitable incubator for 6 h, they were cultured continuously with
another culture medium.
2.2.4. Western blot
RIPA was used to dissociate cells for 10 min at 4 C. The
dissociation solution was centrifuged for 10 min at 4 C with a
centrifuged speed of 14000 r/min. BCA assay was applied to
determine the total protein concentration of the supernate. After
that, 50 mg protein samples were added in 10% SDS-PAGE gel
of every well and the protein was isolated by vertical electro-
phoresis. BIO-RAD wet transfer system was used to transfer
membrane for 80 min with 250 mA. And then they were closed
at room temperature with 5% skim milk for 2 h. The expressions
of corresponding proteins were detected by 1:1000 diluted
MYH9 and b-actin primary antibodies, respectively; 0.01M
TBST was used to wash for 5 min three times. HRP-goat anti-
rabbit second antibody diluted with a ratio of 1:5000 was
combined with target primary antibody and they were incubated
1 h at 37 C. Also, 0.01M TBST was used to wash three times
with 5 min once. ECL solution was dropped on the membrane in
a dark room, and the protein content was examined by BIO-
RAD image system.
2.2.5. Scratch test
After transfected for 24 h, SAOS2 cells were cultivated in 6-
well plates overnight till the fusion degree reached over 90%.
The original medium was sucked out and cells were washed by
PBS solution twice. Cell scratches were made by a 100 uL
axygen and then those residual cells were washed away by PBS
solution. 1 × DMEM culture medium with 5% serum was used
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observe the healing condition of the cell scratches.
2.2.6. Transwell assay
DMEM nutrient solution was used to dilute matrigel with a
ratio of 1:8. After that, it was used to cover on the upper surfaces
of Transwell cell membrane with 100 uL of each well. SAOS2
cells transfected for 72 h were collected and suspended by non-
serum medium to 5 × 105/mL. Then, 250 uL cell suspension was
added into every upper small well while medium with 10% fetal
calf serum was added in the lower wells and they were incubated
in a 5% CO2 incubator at 37 C. Cells without invasion on
membranes and Matrix matrigel were cleared with cotton swabs
and then washed by PBS solution twice, ﬁxed by 4% meta-
formaldehyde and dyed by crystal violet dye. Ten visions were
chosen randomly under times light microscopic to count the cell
number of the well surface. The mean value was used to
represent the invasion ability of SAOS2 cells.
2.2.7. Statistical analysis
All experiment data were analyzed statistically by SPSS 22.0.
Continuous variables were presented by Mean ± SD. Differences
between groups were tested by student's t-test or variance
analysis. Enumeration data were examined by Chi-square test.
P < 0.05 indicated that differences were statistically signiﬁcant.
3. Results
3.1. Expression of MYH9 in osteosarcoma tissues
The results of qRT-PCR showed that the relative expression
quantity of MYH9 mRNA in osteosarcoma tissues was
6.556 ± 0.291, while the benign osteochondroma's was
3.173 ± 0.106. It was proved by statistical analysis that their
relative expression quantities were signiﬁcantly different
(t = 3.448, P < 0.001). A further immunohistochemical staining
was conducted to detect MYH9 protein of osteosarcoma and
osteochondroma tissues of the 65 cases. MYH9 proteins were
mainly located in cytoplasm and cell membrane. Statistical re-
sults revealed that the positive expression rate of MYH9 in os-
teosarcoma tissues was 75.38% (49/65), while the positive
expression rate of MYH9 in osteochondroma tissues was
30.00% (6/20). The results of Chi-square analysis demonstrated
that the expression of MYH9 in osteosarcoma tissues increased
obviously (c2 = 13.794, P < 0.001).
3.2. The positive expression of MYH9 in osteosarcoma
tissues and its correlation with clinical features of
patients
The expression condition of MYH9 in osteosarcoma tissues
and the corresponding clinical data of patients were analyzed by
correlation. The statics results showed that the positive expres-
sion of MYH9 protein in osteosarcoma tissues was positively
correlated with the high Enneking classiﬁcations (III classiﬁca-
tion, c2 = 7.127, P = 0.008) and lung metastasis (c2 = 5.639,
P = 0.018), while it revealed no distinct correlations with age
(c2 = 3.840, P = 0.050), gender (c2 = 0.968, P = 0.325), tumor
diameter (c2 = 2.942, P = 0.086) and histological grade
(c2 = 3.265, P = 0.071), which prompted that MYH9 protein
might have something to do with tumor migration and invasion.3.3. The expression of MYH9 in siRNA silencing SAOS2
cells
With the application of lipidosome method, MYH9 speciﬁc
siRNA and NC siRNA were transferred in the SAOS2 cells. It
was found in the detection of qRT-PCR that MYH9 speciﬁc
siRNA could down-regulate the expression of MYH9 mRNA of
cells signiﬁcantly (1.000 vs. 0.347 ± 0.023, P < 0.001). Western
blot also conﬁrmed that MYH9 speciﬁc siRNA could obviously
down-regulate the expression of protein of cells (0.978 ± 0.031
vs. 0.322 ± 0.010, P < 0.001).
3.4. The inhibitory effect of the expression of silencing
MYH9 on the migration and invasion of SAOS2 cells
After silencing of MYH9 expression in SAOS2 cells, the
results of stretch test showed that the migrant ability of SAOS2
cells of the MYH9 group were decreased signiﬁcantly at 48 h as
compared to that of the NC group (surplus distance of migration
was 22.591 ± 2.127 vs. 72.685 ± 3.032, t = 9.731 P = 0.006).
Furthermore, it was shown by Transwell assay that the number
of invasion cells of the MYH9 group within 24 h were reduced
as compared to that of the NC group (35.398 ± 2.181 vs.
67.184 ± 3.257, t = 9.625, P = 0.007).
4. Discussion
Osteosarcoma is one of the commonest bone tumors pos-
sessing the highest case fatality rate [14]. Due to its complicated
incidence and development biological mechanism, it is difﬁcult
to ﬁnd a molecular therapeutic target, which makes difﬁculty in
beneﬁting from targeted therapy [15,16]. MYH9, as a Ⅱ type
myosin, can be assembled as a two-way polar myosin ﬁlament
after it is activated and then its head and actin combine together
[17,18]. Besides, the Mg+-ATP enzyme in its globular head can
hydrolyze ATP productivity to move myoﬁlament [19] and
generate contractility, which therefore mediates the processes
of cell migration and division [20]. Tumor cell migration is a
main molecular basis of tumor metastasis. Ⅱ type myosin plays
the key role in the movement and chemotaxis processes of
tumor cells [21]. Hence, MYH9 owns great research value in
the process of tumor migration and invasion.
This study proved not only the signiﬁcantly increased
expression of MYH9 mRNA in osteosarcoma tissues by the
detection of qRT-PCR, but also the positive expression of MYH9
existed in more than 75.38% osteosarcoma tissues according to
the results of immuno-histochemical staining. It was discovered
after a more speciﬁc analysis of the clinical pathological ﬁles of
patients that the positive expression of MYH9 was closely related
to the high Enneking classiﬁcation and lung metastasis. It could
be predicted from these clinical data that the high-expressed
MYH9 may play an important in facilitating the invasion and
migration of osteosarcoma. Katono et al [12] has also found in the
researches of lung cancer that the high-expressed MYH9 protein
was closely related to tumor migration indexes such as distant
metastasis of tumor and late TNM classiﬁcation.
To inhibit the migration and invasion abilities of cells is one
of the main micro-mechanisms of anti-tumor migration [22–24].
Mature MYH9 speciﬁc disturbed RNA bought from Santa
Cruz Company (USA) was applied in vitro for silencing the
expression of MYH9 in osteosarcoma SAOS2 cells. The
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osteosarcoma cells could be weakened by decreasing the
expression of MYH9. Meanwhile, the results of Transwell assay
also claimed that the decreased expressed MYH9 could inhibit
the invasion ability of SAOS2 cells were inhibited distinctly,
which hinted that the process of the invasion and metastasis of
osteosarcoma cells could be suppressed effectively by the
decreased MYH9. The occurrence of epithelial–mesenchymal
transition (EMT) is one of the important molecular mechanisms
of the distant metastasis of tumor [25,26]. It was revealed in the
research of breast cancer that MYH9 could inhibit the
formations of epithelial markers E-cadherin and catenin
complexus in MCF-7 cells in breast cancer to mediate the
incidence of epithelial–mesenchymal transition of MCF-
7 cells, as a result, to accelerate the occurrence of tumor
migration [27]. MicroRNA is one of the most worth-studied
molecular targeted therapy nucleotides following after siRNA
[28,29]. Studies have shown that miRNA could silence its
expression by combining with the speciﬁcity of the 30-UTR
area of MYH9 mRNA to suppress the invasion and migration
of colon cancer cells both in vivo and in vitro [30].
In conclusion, MYH9 expressed abnormally high in osteo-
sarcoma tissues and its high expression level is signiﬁcantly
associated with the malignant clinical pathological characteris-
tics of tumor. The migration and invasion of osteosarcoma cells
can be inhibited effectively by decreasing the expression of
MYH9.
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